82_FR_6576 82 FR 6564 - Psychopharmacologic Drugs Advisory Committee; Cancellation

82 FR 6564 - Psychopharmacologic Drugs Advisory Committee; Cancellation

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 82, Issue 12 (January 19, 2017)

Page Range6564-6564
FR Document2017-01170

The meeting of the Psychopharmacologic Drugs Advisory Committee scheduled for February 16, 2017, is cancelled. This meeting was announced in the Federal Register of December 27, 2016 (81 FR 95147). The meeting is no longer needed.

Federal Register, Volume 82 Issue 12 (Thursday, January 19, 2017) 
[Federal Register Volume 82, Number 12 (Thursday, January 19, 2017)]
[Notices]
[Page 6564]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-01170]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]


Psychopharmacologic Drugs Advisory Committee; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Psychopharmacologic Drugs Advisory 
Committee scheduled for February 16, 2017, is cancelled. This meeting 
was announced in the Federal Register of December 27, 2016 (81 FR 
95147). The meeting is no longer needed.

FOR FURTHER INFORMATION CONTACT: Kalyani Bhatt, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, email: [email protected], or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), and follow the prompts to the desired center or 
product area. Please call the Information Line for up-to-date 
information on this meeting.

    Dated: January 11, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-01170 Filed 1-18-17; 8:45 am]
 BILLING CODE 4164-01-P

6564 Federal Register / Vol. 82, No. 12 / Thursday, January 19, 2017 / Notices III. Paperwork Reduction Act of 1995 DEPARTMENT OF HEALTH AND Written/Paper Submissions This draft guidance refers to HUMAN SERVICES Submit written/paper submissions as previously approved collections of follows: Food and Drug Administration • Mail/Hand delivery/Courier (for information found in FDA regulations. These collections of information are written/paper submissions): Division of subject to review by the Office of [Docket No. FDA–2016–N–4389] Dockets Management (HFA–305), Food Management and Budget (OMB) under and Drug Administration, 5630 Fishers Genome Editing in New Plant Varieties Lane, Rm. 1061, Rockville, MD 20852. the Paperwork Reduction Act of 1995 Used for Foods; Request for • For written/paper comments (44 U.S.C. 3501–3520). The collections Comments submitted to the Division of Dockets of information have been approved under OMB Control Nos. 0910–0032, AGENCY: Food and Drug Administration, Management, FDA will post your 0910–0045, 0910–0117, and 0910–0284. HHS. comment, as well as any attachments, except for information submitted, IV. Electronic Access ACTION: Notification; establishment of marked and identified, as confidential, Persons with access to the Internet docket; request for comments. if submitted as detailed in may obtain the draft guidance at either ‘‘Instructions.’’ http://www.fda.gov/AnimalVeterinary/ SUMMARY: The Food and Drug Instructions: All submissions received GuidanceComplianceEnforcement/ Administration (FDA or we) is must include the Docket No. FDA– GuidanceforIndustry/default.htm or announcing the establishment of a 2016–N–4389 for ‘‘Genome Editing in http://www.regulations.gov. docket to receive comments on the use New Plant Varieties Used For Foods; of genome editing techniques to Request for Comments.’’ Received Dated: January 11, 2017. produce new plant varieties that are Leslie Kux, comments will be placed in the docket used for human or animal food. We and, except for those submitted as Associate Commissioner for Policy. invite comment on specific questions ‘‘Confidential Submissions,’’ publicly [FR Doc. 2017–00839 Filed 1–18–17; 8:45 am] contained in this document related to viewable at https://www.regulations.gov BILLING CODE 4164–01–P foods derived from such genome edited or at the Division of Dockets plant varieties. FDA is taking this action Management between 9 a.m. and 4 p.m., to help inform our thinking about foods Monday through Friday. DEPARTMENT OF HEALTH AND derived from new plant varieties • Confidential Submissions—To HUMAN SERVICES produced using genome editing submit a comment with confidential techniques. information that you do not wish to be Food and Drug Administration DATES: Submit either electronic or made publicly available, submit your [Docket No. FDA–2016–N–0001] comments only as a written/paper written comments by April 19, 2017. submission. You should submit two Psychopharmacologic Drugs Advisory ADDRESSES: You may submit comments copies total. One copy will include the Committee; Cancellation as follows: information you claim to be confidential AGENCY: Food and Drug Administration, Electronic Submissions with a heading or cover note that states HHS. ‘‘THIS DOCUMENT CONTAINS Submit electronic comments in the CONFIDENTIAL INFORMATION.’’ We ACTION: Notice. following way: will review this copy, including the SUMMARY: The meeting of the • Federal eRulemaking Portal: claimed confidential information, in our Psychopharmacologic Drugs Advisory https://www.regulations.gov. Follow the consideration of comments. The second Committee scheduled for February 16, instructions for submitting comments. copy, which will have the claimed 2017, is cancelled. This meeting was Comments submitted electronically, confidential information redacted/ announced in the Federal Register of including attachments, to https:// blacked out, will be available for public December 27, 2016 (81 FR 95147). The www.regulations.gov will be posted to viewing and posted on https:// meeting is no longer needed. the docket unchanged. Because your www.regulations.gov. Submit both comment will be made public, you are copies to the Division of Dockets FOR FURTHER INFORMATION CONTACT: solely responsible for ensuring that your Management. If you do not wish your Kalyani Bhatt, Center for Drug comment does not include any Evaluation and Research, Food and name and contact information to be confidential information that you or a made publicly available, you can Drug Administration, 10903 New third party may not wish to be posted, Hampshire Ave., Bldg. 31, Rm. 2417, provide this information on the cover such as medical information, your or sheet and not in the body of your Silver Spring, MD 20993–0002, 301– anyone else’s Social Security number, or 796–9001, FAX: 301–847–8533, email: comments and you must identify this confidential business information, such information as ‘‘confidential.’’ Any PDAC@fda.hhs.gov, or FDA Advisory as a manufacturing process. Please note Committee Information Line, 1–800– information marked as ‘‘confidential’’ that if you include your name, contact will not be disclosed except in 741–8138 (301–443–0572 in the information, or other information that Washington, DC area), and follow the accordance with 21 CFR 10.20 and other identifies you in the body of your applicable disclosure law. For more prompts to the desired center or product comments, that information will be area. Please call the Information Line for information about FDA’s posting of posted on https://www.regulations.gov. comments to public dockets, see 80 FR mstockstill on DSK3G9T082PROD with NOTICES up-to-date information on this meeting. • If you want to submit a comment 56469, September 18, 2015, or access Dated: January 11, 2017. with confidential information that you the information at: http://www.fda.gov/ Janice M. Soreth, do not wish to be made available to the regulatoryinformation/dockets/ Associate Commissioner for Special Medical public, submit the comment as a default.htm. Programs. written/paper submission and in the Docket: For access to the docket to [FR Doc. 2017–01170 Filed 1–18–17; 8:45 am] manner detailed (see ‘‘Written/Paper read background documents or the BILLING CODE 4164–01–P Submissions’’ and ‘‘Instructions’’). electronic and written/paper comments VerDate Sep<11>2014 21:20 Jan 18, 2017 Jkt 241001 PO 00000 Frm 00083 Fmt 4703 Sfmt 4703 E:\FR\FM\19JAN1.SGM 19JAN1


Document Created: 2018-02-01 15:15:23
Document Modified: 2018-02-01 15:15:23
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactKalyani Bhatt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301- 796-9001, FAX: 301-847-8533, email: [email protected], or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting.
FR Citation82 FR 6564 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR